Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood concentrate injection may offer new hope for jaw joint pain

NCT ID NCT07789860

Disease control Sponsor: Suez Canal University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial tests whether injecting platelet-rich fibrin (PRF), made from a patient's own blood, into the jaw joint can improve symptoms of temporomandibular joint (TMJ) internal derangement. Adults aged 18 to 55 with a displaced jaw disc who have not improved with standard care will receive a joint washout (arthrocentesis) with or without the PRF injection. Researchers will measure changes in pain, mouth opening, joint clicking, and disc position using MRI and clinical exams.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Injectable platelet-rich fibrin (PRF), a concentrate from the patient's own blood, injected into the jaw joint after a washout procedure called arthrocentesis.
What this could lead to
If it works, this could offer a simple, low-cost way to ease jaw pain and improve mouth opening for people with TMJ internal derangement, possibly reducing the need for more invasive surgery.
What could go wrong
This is a small trial with only 20 participants, so results may not apply broadly. The procedure involves joint injection, which carries risks like infection or pain, and the benefit over standard arthrocentesis alone is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

20 people

The number who actually took part.

Started

Sep 2023

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with TMJ disc displacement with or without reduction between 18-55years old 2. Patients unresponsive to conservative treatment of TMD 3. Patients with limited mouth opening, painful clicking 4. Pain elicited with joint function Exclusion Criteria: * 1\) Myofacial pain dysfunction syndrome MPDS 2) Patients underwent previous TMJ arthrocentesis, arthroscopy or surgery 3) Pregnancy 4) Patients with systemic diseases that impair soft or hard tissue healing 5)Patients with total joint replacement 6) uncooperative patients, those who wouldn't stick to the follow up periods. 7) hysteric and needle phobic patients ( GA is preferred over Local anesthesia in this situation).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Temporomandibular joint internal derangement are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

temporomandibular joint dysfunction syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Temporomandibular joint internal derangement

Contacts and locations

Locations

  • Faculty of Dentistry Suez canal university

    Ismailia, Ismailia Governorate, 41516, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.